To explore whether NRF2 plays a role in AML of patients with the DNMT3A-R882 mutation, we detected the differential expression of NRF2 in AML patients with DNMT3A-WT and DNMT3A-mutation using the Beat AML database and found that the level of NRF2 was higher in AML patients with the DNMT3A R882 mutation (Fig. 3A). Here, DNMT3A is linked to acute myeloid leukemia.